[Cartilage oligomeric matrix protein (COMP): the role of a non-collagen cartilage matrix protein as a marker of disease activity and joint destruction in patients with rheumatoid arthritis and osteoarthritis]
- PMID: 10408068
- DOI: 10.1007/s003930050156
[Cartilage oligomeric matrix protein (COMP): the role of a non-collagen cartilage matrix protein as a marker of disease activity and joint destruction in patients with rheumatoid arthritis and osteoarthritis]
Abstract
Today, we can assess criteria to predict the tissue destruction and progression of Rheumatoid Arthritis (RA) and Osteoarthritis (OA) only in a late stage of the disease. It would be an advantage to have biochemical markers of disease activity and joint destruction to optimize therapy.
Patients and methods: In this cross-sectional study with 37 RA and 20 OA patients (disease duration 119 +/- 130 months for RA and 41 +/- 73 months for OA), ESR, CRP, disease activity score (DAS), the functional status of RA (American College of Rheumatology), and the radiological scoring systems of Larsen and Kellgren/Lawrence, respectively, were used as parameters for disease activity and joint destruction. Cartilage oligomeric matrix protein (COMP) was measured with an enzyme-linked immunosorbent assay (ELISA) in serum and synovial fluid, COMP fragments with immunoblot in the synovial fluid.
Results: The mean COMP value in synovial fluid was 38 ug/ml (RA) and 46 ug/ml (OA); 6.5 ug/ml (RA) and 3.4 ug/ml (OA) in serum. RA patients had a higher amount of small COMP fragments in synovial fluid than OA patients. In RA patients, there was a significant positive correlation between disease activity (DAS) and COMP in synovial fluid and serum, a negative correlation between functional status of RA and serum COMP and between radiologic joint destruction of the knee and serum COMP. In OA patients, there was a significant correlation of joint space width and synovial fluid COMP.
Discussion: A high clinical disease activity (DAS) correlated with high COMP values in serum and synovial fluid and with increasing proteolytic activity (higher amount of small COMP fragments especially in RA). An increased turnover of cartilage matrix in joint inflammation might explain this correlation. The correlation of decreased COMP with decreased functional status in RA and increased joint destruction is compatible with a loss of cartilage and less turnover. The correlation between joint space width and increased COMP in OA patients with short disease duration might be explained with a higher turnover of the cartilage matrix in the early stage of the disease.
Similar articles
-
Serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and knee osteoarthritis.Clin Rheumatol. 2005 Jun;24(3):278-84. doi: 10.1007/s10067-004-1000-x. Epub 2004 Nov 18. Clin Rheumatol. 2005. PMID: 15940561
-
Small fragments of cartilage oligomeric matrix protein in synovial fluid and serum as markers for cartilage degradation.Br J Rheumatol. 1997 Nov;36(11):1151-60. doi: 10.1093/rheumatology/36.11.1151. Br J Rheumatol. 1997. PMID: 9402858
-
Serum levels of cartilage oligomeric matrix protein. A predicting factor and a valuable parameter for disease management in rheumatoid arthritis.Scand J Rheumatol. 2003;32(3):156-61. doi: 10.1080/03009740310002498. Scand J Rheumatol. 2003. PMID: 12892252 Clinical Trial.
-
Cartilage oligomeric matrix protein level in rheumatic diseases: potential use as a marker for measuring articular cartilage damage and/or the therapeutic efficacy of treatments.Ann N Y Acad Sci. 2007 Jun;1108:398-407. doi: 10.1196/annals.1422.041. Ann N Y Acad Sci. 2007. PMID: 17894003 Review.
-
Exploring the translational potential of clusterin as a biomarker of early osteoarthritis.J Orthop Translat. 2021 Dec 10;32:77-84. doi: 10.1016/j.jot.2021.10.001. eCollection 2022 Jan. J Orthop Translat. 2021. PMID: 34976733 Free PMC article. Review.
Cited by
-
Comparison of modern marker proteins in serum and synovial fluid in patients with advanced osteoarthrosis and rheumatoid arthritis.Rheumatol Int. 2006 Mar;26(5):432-8. doi: 10.1007/s00296-005-0006-2. Epub 2005 Jul 6. Rheumatol Int. 2006. PMID: 16001180
-
Serum levels of cartilage oligomeric matrix protein (COMP): a rapid decrease in patients with active rheumatoid arthritis undergoing intravenous steroid treatment.Rheumatol Int. 2006 Sep;26(11):1001-4. doi: 10.1007/s00296-006-0117-4. Epub 2006 Feb 17. Rheumatol Int. 2006. PMID: 16485108
-
Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities.Arthritis Res Ther. 2011 Apr 28;13(2):215. doi: 10.1186/ar3280. Arthritis Res Ther. 2011. PMID: 21539724 Free PMC article. Review.
-
Serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and knee osteoarthritis.Clin Rheumatol. 2005 Jun;24(3):278-84. doi: 10.1007/s10067-004-1000-x. Epub 2004 Nov 18. Clin Rheumatol. 2005. PMID: 15940561
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous